Deciphera had another bidder before Ono deal; Bristol Myers reports Ph3 fail in lung cancer
Plus, news about OnKure:
Deciphera’s other bidder: Before its acquisition by Ono Pharmaceutical, Deciphera had one other bidder that offered $19.00 per share, according to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.